Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the zilver PTX randomized and single-arm clinical studies

Journal of the American College of Cardiology

Volumn 61, Issue 24, 2013, Pages 2417-2427

  Dake, Michael D ^a   Ansel, Gary M ^b   Jaff, Michael R ^c   Ohki, Takao ^d   Saxon, Richard R ^e   Smouse, H Bob ^f   Snyder, Scott A ^g   O'Leary, Erin E ^g   Tepe, Gunnar ^h   Scheinert, Dierk ⁱ   Zeller, Thomas ^j  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RIVERSIDE METHODIST HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d JIKEI UNIVERSITY HOSPITAL   (Japan)

^e Tri City Medical Center   (United States)

^f OSF SAINT FRANCIS MEDICAL CENTER   (United States)

^g Med Institute Inc Lafayette   (United States)

^h Klinikum Rosenheim   (Germany)

ⁱ Park Hospital   (Germany)

^j UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

more..

Author keywords

angioplasty; drug eluting stent(s); paclitaxel eluting stent(s); peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; TICLOPIDINE;

ADULT; AGED; ARTERY OCCLUSION; ARTICLE; BARE METAL STENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG ELUTING STENT; EVENT FREE SURVIVAL; FEMALE; FEMORAL ARTERY STENT; HUMAN; INTERMETHOD COMPARISON; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; POPLITEAL ARTERY STENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VASCULAR PATENCY;

AGED; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PATIENT SAFETY; POPLITEAL ARTERY; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84878920130     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.03.034     Document Type: Article

References (19)

1. K.R. Goshima, J.L. Mills Sr., and J.D. Hughes A new look at outcomes after infrainguinal bypass surgery: traditional reporting standards systematically underestimate the expenditure of effort required to attain limb salvage J Vasc Surg 39 2004 330 335
2. B.H. Gray, T.M. Sullivan, M.B. Childs, J.R. Young, and J.W. Olin High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty J Vasc Surg 25 1997 74 83
3. K.J. Rocha-Singh, M.R. Jaff, T.R. Crabtree, D.A. Bloch, and G. Ansel Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease Catheter Cardiovasc Interv 69 2007 910 919
4. M. Schillinger, S. Sabeti, and C. Loewe Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery N Engl J Med 354 2006 1879 1888
5. M. Bosiers, G. Torsello, and H.M. Gissler Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study J Endovasc Ther 16 2009 261 269
6. J.R. Laird, B.T. Katzen, and D. Scheinert Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial Circ Cardiovasc Interv 3 2010 267 276
7. S.H. Duda, M. Bosiers, and J. Lammer Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial J Vasc Interv Radiol 16 2005 331 338
8. S.H. Duda, M. Bosiers, and J. Lammer Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial J Endovasc Ther 13 2006 701 710
9. J. Lammer, M. Bosiers, and T. Zeller First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease J Vasc Surg 54 2011 394 401
10. G. Tepe, T. Zeller, and T. Albrecht Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg N Engl J Med 358 2008 689 699
11. M. Werk, S. Langner, and B. Reinkensmeier Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial Circulation 118 2008 1358 1365
12. M.D. Dake, G.M. Ansel, and M.R. Jaff Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results Circ Cardiovasc Interv 4 2011 495 504
13. M.D. Dake, D. Scheinert, and G. Tepe Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study J Endovasc Ther 18 2011 613 623
14. W.R. Hiatt, A.T. Hirsch, J.G. Regensteiner, E.P. Brass Vascular Clinical Trialists Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points Circulation 92 1995 614 621
15. E. Schampaert, J.W. Moses, and J. Schofer Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses Am J Cardiol 98 2006 36 41
16. J.A. Ormiston, M.A. Turco, and J.J. Hall Long-term benefit of the TAXUS Liberte stent in small vessels and long lesions. TASIUS ATLAS program Circ J 75 2011 1120 1129
17. G.W. Stone, S.G. Ellis, and A. Colombo Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program J Am Coll Cardiol Intv 4 2011 530 542
18. J.R. Laird, B.T. Katzen, and D. Scheinert Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial J Endovasc Ther 19 2012 1 9
19. M. Schillinger, S. Sabeti, and P. Dick Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting Circulation 115 2007 2745 2749